Arcus Biosciences Gross Profit 2017-2022 | RCUS

Arcus Biosciences gross profit from 2017 to 2022. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
Arcus Biosciences Annual Gross Profit
(Millions of US $)
2021 $383
2020 $78
2019 $15
2018 $8
2017 $1
2016 $
Arcus Biosciences Quarterly Gross Profit
(Millions of US $)
2022-09-30 $34
2022-06-30 $27
2022-03-31 $18
2021-12-31 $354
2021-09-30 $9
2021-06-30 $9
2021-03-31 $9
2020-12-31 $9
2020-09-30 $65
2020-06-30 $2
2020-03-31 $2
2019-12-31 $10
2019-09-30 $2
2019-06-30 $2
2019-03-31 $2
2018-12-31 $2
2018-09-30 $4
2018-06-30 $1
2018-03-31 $1
2017-12-31 $1
2017-09-30 $0
2017-06-30
2017-03-31
2016-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.073B $0.383B
Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $168.264B 10.27
GSK (GSK) United Kingdom $68.657B 8.61
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.145B 19.02
Ginkgo Bioworks Holdings (DNA) United States $3.570B 0.00
Myovant Sciences (MYOV) United Kingdom $2.594B 0.00
Biohaven (BHVN) United States $0.982B 0.00
Emergent Biosolutions (EBS) United States $0.579B 4.55
Zymeworks (ZYME) Canada $0.493B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.261B 0.00
Enzo Biochem (ENZ) United States $0.094B 0.00
SQZ Biotechnologies (SQZ) United States $0.078B 0.00
Gelesis Holdings (GLS) United States $0.028B 0.00
Ambrx Biopharma (AMAM) United States $0.019B 0.00